April 2023 Top Biopharma Deal: DualityBio development and commercialization deal with BioNTech for DB-1303 and DB-1311 for cancer
April 2023 Top Biopharma Deal Upfront
DualityBio development and commercialization deal with BioNTech for DB-1303 and DB-1311
Highlighted Deal Financial Comps
Date Announced:
April 3, 2023
Total Deal Value:
$1.67B
Upfront Cash:
$170M
Upfront Equity:
n/a
Option Payments:
n/a
Total Milestones:
Up to $1.5B in development, regulatory, and sales milestone payments.
Royalties:
Single-digit to double-digit tiered royalties.
Cost & Profit Split:
DualityBio retains a co-development/co-promotion cost and profit/loss sharing option for DB-1311 in the U.S. market.
Deal Synopsis
The Asset:
DB-1303, a topoisomerase-1 inhibitor-based ADC, and DB-1311 for the treatment of human cancers.
Deal Structure:
Dev and Commercial License
Partnership Features:
Co-Development, Shared Dev Cost , Co-Promotion, Shared Promotion Cost , Options to Add Products, TAs, and/or Territories
Deal Details:
-
- DualityBio granted BioNTech exclusive, worldwide rights, excluding China, Hong Kong, and Macau, to develop and commercialize DB-1303, a topoisomerase-1 inhibitor-based ADC, and DB-1311 for the treatment of human cancers.
- DualityBio has the option to co-develop and co-promote DB-1311 in the U.S. with cost and profit/loss sharing.
- DualityBio will receive $170M up front and is eligible for up $1.5B in development, regulatory, and sales milestones, plus single-digit to double-digit tiered royalties.
Last Month:
Congrats to DualityBio and BioNTech for landing DealForma’s April 2023 Top Biopharma Deal. Last month’s Deal of the Month was OncoC4 – BioNTech for ONC-392. Read about it here.
DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.
We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
20,378
Licensing Deals
17,730
Funding Rounds
4,034
M&A
31,012
Company Profiles
5,478
Other Deals
26,505
Drug Sales Figures
All of this by stage, disease indication, modality, target...
More Research by DealForma
Introducing: DealForma plus Tableau
We are excited to introduce DealForma's new Tableau dashboard integration. High quality data on biopharma deals and funding meets interactive charts and visuals. DealForma customers will have exclusive access to the DealForma chart dashboards built on Tableau right...
Venture & IPO – Medtech – Q1 2023
The Medtech sector encompasses medical devices, diagnostics, and digital health solutions, playing a crucial role in healthcare. In Q1 2022, the medtech, devices, digital health therapeutics, and wearables sector experienced a strong opening with 95 funding rounds and...